HC Wainwright & Co. Downgrades Asensus Surgical to Neutral, Lowers Price Target to $0.35
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Asensus Surgical (AMEX:ASXC) from Buy to Neutral and significantly lowered the price target from $2 to $0.35.
April 04, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Asensus Surgical was downgraded from Buy to Neutral by HC Wainwright & Co., and the price target was reduced from $2 to $0.35.
The downgrade from Buy to Neutral by a reputable analyst firm, coupled with a significant reduction in the price target, is likely to negatively impact investor sentiment and the short-term stock price of Asensus Surgical. Such a drastic change in both rating and price target suggests a less favorable outlook on the company's future performance or market conditions, leading to potential selling pressure.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100